Joe Palca

Joe Palca is a science correspondent for NPR. Since joining NPR in 1992, Palca has covered a range of science topics — everything from biomedical research to astronomy. He is currently focused on the eponymous series, "Joe's Big Idea." Stories in the series explore the minds and motivations of scientists and inventors. Palca is also the founder of NPR Scicommers – A science communication collective.

Palca began his journalism career in television in 1982, working as a health producer for the CBS affiliate in Washington, DC. In 1986, he left television for a seven-year stint as a print journalist, first as the Washington news editor for Nature, and then as a senior correspondent for Science Magazine.

In October 2009, Palca took a six-month leave from NPR to become science writer in residence at The Huntington Library, Art Collections, and Botanical Gardens.

Palca has won numerous awards, including the National Academies Communications Award, the Science-in-Society Award of the National Association of Science Writers, the American Chemical Society's James T. Grady-James H. Stack Award for Interpreting Chemistry for the Public, the American Association for the Advancement of Science Journalism Prize, and the Victor Cohn Prize for Excellence in Medical Writing. In 2019, Palca was elected to the American Academy of Arts and Sciences for outstanding achievement in journalism.

With Flora Lichtman, Palca is the co-author of Annoying: The Science of What Bugs Us (Wiley, 2011).

He comes to journalism from a science background, having received a Ph.D. in psychology from the University of California at Santa Cruz, where he worked on human sleep physiology.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

Historically, tobacco plants are responsible for their share of illness and death. Now they may help control the COVID-19 pandemic.

Two biotech companies are using the tobacco plant, Nicotiana benthamiana, as bio-factories to produce a key protein from the coronavirus that can be used in a vaccine.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

RACHEL MARTIN, HOST:

Companies trying to make a vaccine for COVID-19 are trying a variety of approaches. Most involve laboratories capable of sophisticated biotechnology, but NPR's Joe Palca has this report about one approach for creating a vaccine which starts in a greenhouse.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

Moncef Slaoui, chief adviser to the Trump administration's Operation Warp Speed program, has sketched out the timetable for when he thinks a COVID-19 vaccine could be ready, at least for some people living in the United States.

And Election Day doesn't figure into his forecast.

He made his predictions during an online symposium organized by Johns Hopkins University and the University of Washington on Tuesday.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

President Trump's medical team announced on Sunday that it had decided to treat the president with dexamethasone.

It was a decision that struck some doctors and COVID-19 specialists as surprising, given the fact that Dr. Sean Conley, the president's doctor, gave a fairly upbeat assessment of his patient's condition. Typically, only hospitalized COVID-19 patients in need of oxygen are given the drug.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

All right, now let's work through what treatments the president is getting and what they tell us with NPR science correspondent Joe Palca. Good morning, Joe.

JOE PALCA, BYLINE: Good morning.

White House physician Sean Conley says that President Trump was doing "very well" and that the symptoms he had are resolving and improving.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

SCOTT SIMON, HOST:

Updated at 7:00 a.m. ET

More than 100,000 people are taking part in studies to see if one or more COVID-19 vaccine candidates actually work.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

SACHA PFEIFFER, HOST:

Drugmaker AstraZeneca announced Saturday that its COVID-19 vaccine studies have resumed in the United Kingdom, though not yet in the United States. The vaccine trials had been placed on hold around the world earlier in the week after a U.K. participant in one of the studies developed a neurological illness.

Drugmaker AstraZeneca has announced that it is pausing its COVID-19 vaccine trial because of a "potentially unexplained illness" in one of the trial volunteers.

The vaccine was developed by the University of Oxford in partnership with AstraZeneca. It's being studied in thousands of patients in the United States and the United Kingdom. The illness apparently occurred in a U.K. volunteer.

Pages